Health / Medical Topics

    MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells

    Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses. (NCI Thesaurus)




    YOU MAY ALSO LIKE

    A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential…
    A peptide-based cancer vaccine consisting of amino acid residues 26 through 35 of MART-1 (melanoma antigen recognized by T-cells-1) with a leucine…
    A cancer vaccine consisting of an attenuated recombinant vaccinia virus expressing the melanoma-associated antigen MART-1. Vaccination with this agent may stimulate cytotoxic…
    Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A)…
    A synthetic cancer vaccine derived from a melanoma-associated antigen, MART-1. Antigenic peptides derived from MART-1 are recognized by CD8+ T lymphocytes…
    A protein found on normal melanocytes (cells that make the pigment melanin) in the skin and in the retina. It is also…

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact